New Hope, MN, United States

Will Nasrallah’s Demise Save Netanyahu?

The Israeli leader is taking credit for weakening Hezbollah.

2024-10-02 11:00

NEFECON Included in 2024 KDIGO Clinical Practice Guidelines

NEFECON Included in 2024 KDIGO Clinical Practice Guidelines

2024-10-02 03:48

Climate Change 2024: Dr. Robin Ganzert On Leadership Through Challenge

This week New York City's Climate Week welcomed more than 6,500 people from over 100 countries to attend over 600 events and activities across the city.

2024-09-30 17:15

Arrhythmogenic Cardiomyopathy (ACM) Market Research Report 2024: US and EU5 Epidemiology, Treatment Landscape, Unmet Needs, Emerging Therapies, and Value & Access

Dublin, Sept. 30, 2024 (GLOBE NEWSWIRE) -- The "Arrhythmogenic Cardiomyopathy (ACM) Market Assessment: Epidemiology, Treatment Landscape, Unmet Needs, Emerging Therapies, and Value & Access" report has been added to ResearchAndMarkets.com's offering.

2024-09-30 09:26

Seizing Israel's success against Hezbollah for a new Middle East strategy

Israel’s recent achievements against Hezbollah offer a unique opportunity for strategic alliances and regional stability, but swift political action is needed to capitalize on this success.

2024-09-30 03:16

Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved lung function and also improved health-related quality of l…

2024-09-27 11:00

Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD

Dupixent approved in China as the first-ever biologic medicine for patients with COPD Approval follows EU approval of Dupixent for adults with COPD...

2024-09-27 11:00

Drug may boost motivation for people with depression

"It's exciting to see how modulating inflammation can directly influence motivation, one of the most challenging symptoms to treat in depression."

2024-09-25 19:24

Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer

− Approval Based on Results from Positive, Global, Phase 3 FRESCO-2 Trial − FRUZAQLA (fruquintinib) is the First Novel Targeted Therapy in Japan for Metastatic Colorectal Cancer (mCRC) Regardless of Biomarker Status in Over a Decade OSAKA, Japan & CAMBRIDGE, …

2024-09-24 07:10

HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda

— Approval based on results from global Phase III FRESCO-2 trial in patients with previously treated metastatic colorectal cancer — — Fruquintinib...

2024-09-24 07:00